Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients

Kweku A. Appau, Victor W. Fazio, Bo Shen, James M. Church, Bret Lashner, Feza Remzi, Aaron Brzezinski, Scott A. Strong, Jeffrey Hammel, Ravi P. Kiran

Research output: Contribution to journalArticlepeer-review

198 Scopus citations

Abstract

Background: Few studies have evaluated preoperative infliximab use and postoperative outcomes in Crohn's patients. Our aim was to evaluate 30-day postoperative outcomes for Crohn's patients treated with infliximab within 3 months prior to ileocolonic resection. Methods: The study is a retrospective evaluation of data for patients undergoing ileocolonic resection after 1998 from a prospective Crohn's disease database. Patient characteristics and 30-day complications were compared for patients treated with infliximab within 3 months before surgery and an infliximab naïve group. The infliximab group was also compared with non-infliximab patients undergoing ileocolonic surgery before 1998. Results: Sixty of 389 Crohn's patients undergoing ileocolonic resection received infliximab. The infliximab and non-infliximab groups had similar characteristics, preoperative risk factors, and surgical procedure. However, steroid use was higher (p<0.05) in the non-infliximab group while concurrent immunosuppressive use was higher (p<0.001) in the infliximab group. Multivariate analysis showed infliximab use to be associated with 30-day postoperative readmission (p=0.045), sepsis (p=0.027), and intraabdominal abscess (p=0.005). The presence of diverting stoma (n=17) in the infliximab group was associated with lower risk of sepsis (0% vs. 27.9%, p=0.013). Similar results were noted when the infliximab group was compared to the pre-infliximab patients. Conclusions: Infliximab use within 3 months before surgery is associated with increased postoperative sepsis, abscess, and readmissions in Crohn's patients. Diverting stoma may protect against these complications.

Original languageEnglish (US)
Pages (from-to)1738-1744
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2008

Keywords

  • Abscess
  • Anastomotic leak
  • Crohn's disease
  • Ileocolonic resection
  • Infliximab
  • Postoperative complications
  • Readmissions
  • Sepsis

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Fingerprint Dive into the research topics of 'Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients'. Together they form a unique fingerprint.

Cite this